Professional background
I am a Director in Fieldfisher's Corporate team, specialising in Equity Capital Markets. I have experience of both Main Market and AIM IPO's, fundraisings and acquisitions. I regularly act for issuers and investment banks alike and am confident in negotiating each aspect of a transaction. I am happy to advise on discrete questions concerning matters of corporate law and governance and have a particular interest in life sciences and renewables. During 2023/2024, I spent eight months on secondment with the in-house legal team of investment bank, Liberum Capital. Whilst there, I sat within the investment banking room and additionally supported the internal team on Liberum’s merger with Panmure Gordon.
Education
I earned an Upper Second Class Honours degree from the University of Warwick
Notable deals
Advised Allenby Capital, Dowgate Capital & Stifel Nicolaus Europe on the c£100m fundraising and acquisition for Franchise Brands plc
Advised Berenberg & Tamesis on their Main Market £40m fundraising and Class 1 transaction for Capital Limited
Advised CT Automotive Group plc on their initial public offering and subsequent fundraises
Advised EnSilica plc on their placing and admission to AIM
Advised Gelion plc on their initial public offering and all subsequent fundraises
Advised InnovaDerma plc on their Main Market Placing and Open Offer, and subsequently on their recommended merger with Brand Architekts Group plc
Advised Panmure Gordon on the AIM IPO of Dianomi
Advised SigmaRoc plc in connection with a £260 million fundraising to fund the €470 million acquisition of Finnish limestone producer Nordkalk Corporation
Advised Stifel and Cenkos on the AIM IPO of GENinCode
Advised Synairgen on their £87m Placing, US Placing & Open Offer to fund their Phase III Clinical Trials, representing one of the largest biotech fundraisings on AIM for several years